Neurofibromatosis type 1 (NF1) is a genetic condition that disrupts how certain cells grow and divide, leading to tumors along nerves and a wide range of effects on the skin, skeleton, eyes, and brain. It affects roughly 1 in every 3,000 people worldwide, making it one of the most common single-gene disorders. The condition is inherited in an autosomal dominant pattern, meaning a single copy of the faulty gene is enough to cause it, though the way it shows up varies enormously from person to person.
What Causes NF1 at the Genetic Level
NF1 is caused by mutations in the NF1 gene, which sits on chromosome 17 and carries the instructions for a protein called neurofibromin. Neurofibromin acts as a brake on a cell-growth signal called Ras. Specifically, it speeds up the conversion of Ras from its active state to its inactive state. When the gene is mutated and neurofibromin doesn’t work properly, Ras stays switched on longer than it should, pushing cells toward excessive growth, division, and survival.1Communications Biology. The therapeutic potential of neurofibromin signaling pathways and binding partners That overactive growth signaling is why NF1 is fundamentally a tumor-predisposition syndrome: cells that should stop dividing keep going.
About half of all NF1 cases are inherited from a parent who has the condition. The other half arise from brand-new mutations that occur spontaneously, with no family history at all. The mutation rate for the NF1 gene is unusually high compared with most human genes, though researchers still don’t fully understand why.2American Journal of Medical Genetics. Epidemiology of neurofibromatosis type 1 Despite being a single-gene disorder, its expression is highly variable and unpredictable, even among members of the same family carrying the exact same mutation.3Journal of Medical Genetics. Neurofibromatosis type 1: from genotype to phenotype One sibling might have a mild form with mostly cosmetic features, while another could develop serious complications.
That said, certain specific mutations do correlate with more severe disease. Missense mutations affecting a particular stretch of the gene (codons 844–848) have been linked to a more severe clinical picture, which is useful information for genetic counselors working with newly diagnosed families.4American Journal of Human Genetics. Genotype-phenotype correlation in neurofibromatosis type 1: evidence for a severe phenotype associated with missense mutations affecting NF1 codons 844–848 These genotype-phenotype links are still the exception rather than the rule, however. For most people with NF1, knowing the exact mutation does not predict how severe the condition will be.
The First Signs and How Doctors Make the Diagnosis
The earliest and most recognizable feature of NF1 is café-au-lait macules: flat, light-brown patches on the skin that resemble the color of milky coffee. Many children are born with one or two of these spots, which is completely common and usually meaningless. What raises a red flag is the number. Among patients evaluated in one study, having five or more café-au-lait macules at birth correlated with a likelihood of NF1 as high as 95%. Interestingly, the absence of these spots at birth did not rule NF1 out, and a higher number of spots was also associated with a greater chance of developing plexiform neurofibromas later on.5PubMed Central. Café-Au-Lait Macules in Neurofibromatosis Type 1: Birthmark or Biomarker?
Diagnosis has traditionally relied on a set of clinical criteria, and an international consensus group revised those criteria in 2021 to incorporate advances in genetics, imaging, and dermatology. The updated criteria now formally include genetic testing and clarify the diagnosis of mosaic NF1, a form in which only some of the body’s cells carry the mutation. Other revisions included replacing the older criterion of “thinning of a long bone” with “anterolateral bowing of the lower limb,” which is easier to recognize clinically.6PubMed Central. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation The revised criteria don’t require genetic testing for diagnosis — a person can still be diagnosed purely on clinical findings — but molecular testing is increasingly important in ambiguous cases.
One reason molecular testing matters is a condition called Legius syndrome. In young children who have multiple café-au-lait macules and freckling but nothing else, Legius syndrome and NF1 look identical on a physical exam. The two conditions involve different genes (NF1 versus SPRED1), and Legius syndrome carries a much milder prognosis without the tumor risk. Genetic testing is usually the only way to tell them apart early on.7PubMed Central. Legius Syndrome and its Relationship with Neurofibromatosis Type 1
Neurofibromas and Other Tumors
The hallmark tumors of NF1 are neurofibromas — benign growths that develop from the cells surrounding nerves. They come in several forms. Cutaneous neurofibromas are small, soft bumps on or just under the skin. They are almost never dangerous, but they can number in the hundreds or even thousands in adults, causing cosmetic distress and chronic itching. The number of cutaneous neurofibromas tends to increase during adulthood, and hormonal changes such as puberty and pregnancy may accelerate their growth, though the hormonal connection is still considered hypothetical. Steroid hormone receptors have been found on neurofibroma tissue, and lab studies have shown that Schwann cells respond to progesterone and estradiol.8Oxford Academic (British Journal of Dermatology). Neurofibromatosis type 1: neurofibromas and sex
Plexiform neurofibromas are a different and more serious category. These grow along the length of a nerve and can become very large, infiltrating surrounding tissue. A study that classified plexiform neurofibromas by their growth pattern found three types: superficial tumors that mainly caused cosmetic issues, displacing tumors that were associated with pain and disfigurement, and invasive tumors that most often led to functional problems. Over half of the invasive type occurred in the face, head, and neck.9PubMed. MRI growth patterns of plexiform neurofibromas in patients with neurofibromatosis type 1 Plexiform neurofibromas grow faster in children and tend to slow down with age. In a study following over 200 patients, tumors grew at a median rate of roughly 4% per year, and that rate was inversely correlated with age. About a third of tumors actually got smaller over follow-up.10PubMed Central. Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1
The most feared complication is malignant transformation. A small percentage of plexiform neurofibromas can evolve into malignant peripheral nerve sheath tumors (MPNSTs), an aggressive form of cancer. These arise from the malignant transformation of benign plexiform neurofibromas or borderline atypical neurofibromas.11PubMed Central. Contemporary Approach to Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors Warning signs that should prompt urgent evaluation include rapid growth of an existing tumor, new or worsening pain, and changes in the texture of a previously soft lump.
Effects on the Eyes, Bones, and Brain
NF1 affects far more than the skin. Children with NF1 are prone to developing low-grade gliomas, particularly along the optic pathway — the nerves and structures that carry visual information from the eyes to the brain. These optic pathway gliomas (OPGs) are among the most common brain tumors in NF1, and between roughly 35% and 50% of children who develop them experience reduced visual acuity.12PubMed Central. Optic Pathway Gliomas in Neurofibromatosis Type 1 Many OPGs are discovered before symptoms appear, during routine screening, and not all of them require treatment. Some remain stable or even regress on their own.
The skeleton is another system commonly involved. Bone-related complications include scoliosis, abnormal curvature of the spine, bowing of the long bones (particularly the tibia), and pseudarthrosis — a condition where a fractured bone fails to heal and forms a false joint instead.13PubMed Central. Current Aspects on the Pathophysiology of Bone Metabolic Defects during Progression of Scoliosis in Neurofibromatosis Type 1 These skeletal problems often show up early in childhood and can require surgical intervention.
Cognitive and learning difficulties are among the most common features of NF1, yet they receive less public attention than the visible tumors. Research has consistently shown that the average IQ distribution in people with NF1 is shifted downward compared with the general population, and the pattern appears to split into two groups: those with and those without some degree of cognitive impairment. MRI studies have found that about 60% of children with NF1 show areas of increased signal on brain scans, sometimes called focal areas of signal intensity (FASI) or unidentified bright objects. Children with these brain changes had significantly lower IQ and language scores and were at higher risk for academic difficulties, while children without these changes performed similarly to the general population.14PubMed. Specific learning disability in children with neurofibromatosis type 1: significance of MRI abnormalities More recent work has found that the location of these signal changes matters too. Patients with changes in the cerebellum or brainstem had higher performance IQ scores than those with changes in other regions, and both patients who had intellectual disability in the study had changes in the thalamus.15PubMed. Focal areas of signal intensity in neurofibromatosis type 1: Correlation between MRI findings and cognitive function
Cardiovascular and Other Systemic Complications
NF1 can also involve the blood vessels, a dimension of the disease that is easy to overlook. Vascular complications include stenosis (narrowing) and aneurysms in various arteries, including the renal arteries. One case report described a woman in her early twenties who presented with a hypertensive crisis and was found to have multiple microaneurysms in her kidneys along with classic skin features of NF1.16PubMed Central. Neurofibromatosis type 1 first presented as hypertensive crisis
Another vascular concern is pheochromocytoma, a rare tumor of the adrenal gland that produces excess adrenaline-like hormones and can cause dangerous spikes in blood pressure. In one study of NF1 patients, about 15% were found to have a pheochromocytoma, and nearly 30% had arterial hypertension. Over half of those with pheochromocytomas had symptoms at the time of diagnosis.17PubMed. Neurofibromatosis type 1 (NF1) and pheochromocytoma: prevalence, clinical and cardiovascular aspects For someone with NF1 who develops unexplained high blood pressure, screening for pheochromocytoma is an important step.18PubMed Central. Pheochromocytoma and Neurofibromatosis Type 1 in a Patient with Hypertension
Living With NF1 and the Burden of Plexiform Neurofibromas
The day-to-day reality of NF1, particularly for adults with symptomatic plexiform neurofibromas, can be heavy. A U.S. survey of 120 adults with NF1 and plexiform tumors found that 80% reported experiencing pain and fatigue. Over half described moderate-to-severe chronic tumor pain, and the average spike pain score was above 6 on a 10-point scale. Quality-of-life scores across physical function, depression, anxiety, and fatigue were all worse than the general population. Only about 13% of participants were employed, and half reported being on disability.19PubMed Central. Clinical and Humanistic Burden Among Adults with Neurofibromatosis Type 1 and Symptomatic Plexiform Neurofibroma in the United States A UK-based survey told a broadly similar story, with patients scoring well below age-matched norms on general health utility measures and reporting high rates of pain, anxiety, depression, and chronic itching.20PubMed Central. Impact of neurofibromatosis type 1 with plexiform neurofibromas on the health-related quality of life and work productivity of adult patients and caregivers in the UK: a cross-sectional survey
These numbers reflect the population with symptomatic plexiform neurofibromas specifically, which represents the more severe end of the NF1 spectrum. Many people with NF1 live much less affected lives, particularly those whose disease is limited to skin findings and mild learning differences. But the data underscores why multidisciplinary care matters. European expert recommendations advise clinical assessment by an NF1 specialist at least annually for children under 10, every two years for older children, and every three years for adults, with more frequent visits during the transition to adulthood.21The Lancet. European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS) expert recommendations for the surveillance and management of tumours in neurofibromatosis type 1 French national guidelines emphasize that management should be patient-centered, longitudinal, and involve communication across specialties including dermatology, neurology, orthopedics, ophthalmology, and oncology.22PubMed Central. Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966
The First Targeted Drug and What Came After
For decades, the only option for problematic plexiform neurofibromas was surgery, and many of these tumors are inoperable because of their location or how deeply they are intertwined with nerves and surrounding tissue. That changed in 2020 when the FDA approved selumetinib, the first drug specifically for NF1-related plexiform neurofibromas in children. In the pivotal trial, 70% of children with inoperable plexiform neurofibromas had confirmed tumor shrinkage, and most of those responses lasted a year or more. Beyond the scans, patients reported improvement in motor skills, reduced pain, and better quality of life.23PubMed Central. Selumetinib in Children with Inoperable Plexiform Neurofibromas24PubMed Central. The Use of MEK Inhibitors in Neurofibromatosis Type 1–Associated Tumors and Management of Toxicities
Selumetinib works by blocking an enzyme called MEK, which sits in the overactive Ras signaling chain described earlier. It doesn’t fix the underlying gene defect, but it dials down the growth signals that the defect amplifies. Since selumetinib’s approval, other drugs targeting the same pathway have shown promise. Cabozantinib and mirdametinib have demonstrated activity in adults, and additional MEK inhibitors including trametinib and binimetinib have reported encouraging early results.25PubMed Central. Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review Expanding the options beyond a single drug is important because not everyone tolerates selumetinib well, and adults — who were not included in the pivotal trial — need effective therapies too.
Gene Therapy and Experimental Approaches
The ultimate goal would be to fix or compensate for the broken NF1 gene itself. Several experimental strategies are being explored, including gene therapy using viral vectors to deliver a working copy of the gene, engineered viruses that selectively destroy tumor cells with overactive Ras signaling, and immune-cell therapies designed to target NF1-associated tumors.26PubMed Central. Neurofibromatosis Type 1: Genetic Mechanisms and Advances in Therapeutic Innovation These are still in early stages. Researchers have pointed out that despite intense interest stretching back decades, fundamental challenges remain: figuring out the best method for restoring gene function, getting the therapy to the right cell types, and ensuring it works safely in people rather than just in lab models.27PubMed. Gene-targeted therapy for neurofibromatosis and schwannomatosis: The path to clinical trials Animal models have been useful for understanding NF1 biology but have been less helpful for modeling specific tumors.28PubMed Central. Mouse models of neurofibromatosis 1 and 2 For now, gene therapy for NF1 remains a research-stage ambition, not an imminent clinical reality.
Family Planning When NF1 Is in the Picture
Because NF1 follows an autosomal dominant inheritance pattern, a person with the condition has a 50% chance of passing the mutation to each child. For families who want to avoid this, preimplantation genetic testing (PGT) combined with in vitro fertilization is an option. This involves testing embryos for the NF1 mutation before implantation and selecting only unaffected ones for transfer.29PubMed Central. Decision-Making Around Preimplantation Genetic Testing by Individuals With Neurofibromatosis Type I: A Qualitative Study For some families, this may be the only acceptable way to ensure the birth of unaffected children.30PubMed. Preimplantation genetic diagnosis for neurofibromatosis type 1
The decision is not straightforward for everyone. NF1 is so variable that some people with mild forms feel the condition is manageable and do not pursue genetic selection. Others, particularly those who have experienced severe complications, feel strongly about preventing transmission. Because the severity of the disease cannot be predicted from the mutation alone, even within the same family, the counseling conversation is genuinely complex. This is one area where working with a genetic counselor who specializes in NF1 can make a real difference.
How Long Has NF1 Been Recognized
NF1 has a surprisingly deep history. The first scientifically grounded description of what we now call NF1 appeared in 1768, when the English physician Mark Akenside recognized that the “monsters” described by earlier scholars actually suffered from a disorder of the nerves.31PubMed. A history of von Recklinghausen’s NF1 The nerve tumors themselves were first detailed by Robert Smith in 1849, but the condition is most closely associated with the German pathologist Friedrich von Recklinghausen, who published a landmark description in 1882 and gave the disorder its name.32PubMed Central. Neurofibromatosis: chronological history and current issues For over a century, “von Recklinghausen’s disease” was the standard term. The NF1 gene itself was not identified until 1990, and the explosion of molecular understanding since then has fundamentally reshaped how the condition is diagnosed, monitored, and increasingly treated.